---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-001237"
form_type: "8-K"
ticker: "MTNB"
cik: "0001582554"
company_name: "Matinas BioPharma Holdings, Inc."
filed_at: "2023-01-12T23:59:59+00:00"
generated_at: "2026-06-20T16:01:18.728192+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Matinas BioPharma partners with Resilience to explore oral nucleic acid delivery via LNC platform

## Summary
- Material Transfer and Evaluation Agreement with National Resilience for oral delivery of nucleic acids.
- Research program includes design, formulation, optimization, and in vitro/in vivo testing of nucleic acids with LNC platform.
- Collaboration is distinct from ongoing work with BioNTech, allowing simultaneous platform development.
- No financial terms disclosed; partnership aims to demonstrate LNC platform capabilities.

## SEC filing metadata
- accession: 0001493152-23-001237
- form_type: 8-K
- ticker: MTNB
- cik: 0001582554
- company_name: Matinas BioPharma Holdings, Inc.
- filed_at: 2023-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582554/000149315223001237/0001493152-23-001237-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582554/000149315223001237/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-001237
- JSON: https://secwatch.observer/filing/0001493152-23-001237.json
- Plain text: https://secwatch.observer/filing/0001493152-23-001237.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.